Agenix Limited Announces Initial China Sales of Hep B Drug YouHeDing

January 4, 2007 -- Australian biotech Agenix (ASX: AGX) reported that its new treatment for hepatitis B notched sales of 10 million RMB ($1.4 million) in December, its first month on the market. YouHeDing, as the treatment is known, was approved by the SFDA in October 2007. According to Agenix, YouHeDing (adefovir dipivoxil tablets) has a novel crystalline structure when compared to other approved versions of adefovir dipivoxil. It is the first triclinic structured form of the drug developed and patented in China. More details...